Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514781449> ?p ?o ?g. }
- W2514781449 endingPage "1541" @default.
- W2514781449 startingPage "1531" @default.
- W2514781449 abstract "The recent results of Protocol T have illustrated the efficacy of aflibercept in the treatment of diabetic macular edema. It also demonstrated that in patients with poor vision (<6/12), aflibercept offers anatomical and visual advantages over ranibizumab and bevacizumab in the first 12 months of treament. At 2 years, the difference between the three drugs decreased with patients with a better baseline VA (69–78) showing a statistically insignificant advantage for ranibizumab compared with aflibercept.These results were achieved using a pro-re nata (PRN) protocol, which was not previously studied in large phase 3 trials, VIVID and VISTA, that chose to compare the 2.0 mg dose in a monthly and bimonthly regimen. In this review article, we analyzed earlier studies such as DAVINCI and VIVID and VISTA to determine which treatment strategy offers the best results; monthly, bimonthly, or PRN. We also studied the different doses for aflibercept used in DAVINCI to determine which is more effective the 0.5 mg dose or the 2.0 mg dose. In addition, we analyzed the recent data from protocol T with regards to visual and anatomic outcomes to try to determine whether these results concur with previous studies. Finally, we discuss the role of aflibercept as a potential alternative to any diabetic macular edema regimen regardless what the primary drug used is." @default.
- W2514781449 created "2016-09-16" @default.
- W2514781449 creator A5019950558 @default.
- W2514781449 creator A5063176118 @default.
- W2514781449 creator A5064089237 @default.
- W2514781449 creator A5067288250 @default.
- W2514781449 date "2016-08-26" @default.
- W2514781449 modified "2023-10-09" @default.
- W2514781449 title "Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option" @default.
- W2514781449 cites W1499805048 @default.
- W2514781449 cites W1574902248 @default.
- W2514781449 cites W1652166925 @default.
- W2514781449 cites W1782108791 @default.
- W2514781449 cites W1786299986 @default.
- W2514781449 cites W1816809098 @default.
- W2514781449 cites W1979831185 @default.
- W2514781449 cites W1980342089 @default.
- W2514781449 cites W1980632047 @default.
- W2514781449 cites W1980725734 @default.
- W2514781449 cites W1990374749 @default.
- W2514781449 cites W1993881088 @default.
- W2514781449 cites W1996171994 @default.
- W2514781449 cites W2022827671 @default.
- W2514781449 cites W2022886290 @default.
- W2514781449 cites W2036712095 @default.
- W2514781449 cites W2041647424 @default.
- W2514781449 cites W2042362462 @default.
- W2514781449 cites W2049577742 @default.
- W2514781449 cites W2054252209 @default.
- W2514781449 cites W2067579161 @default.
- W2514781449 cites W2073990613 @default.
- W2514781449 cites W2075984382 @default.
- W2514781449 cites W2077547109 @default.
- W2514781449 cites W2077932437 @default.
- W2514781449 cites W2079713841 @default.
- W2514781449 cites W2083043469 @default.
- W2514781449 cites W2091407629 @default.
- W2514781449 cites W2091729420 @default.
- W2514781449 cites W2092886764 @default.
- W2514781449 cites W2102463203 @default.
- W2514781449 cites W2102946567 @default.
- W2514781449 cites W2121058595 @default.
- W2514781449 cites W2122668687 @default.
- W2514781449 cites W2123241447 @default.
- W2514781449 cites W2156799887 @default.
- W2514781449 cites W2157204458 @default.
- W2514781449 cites W2160745487 @default.
- W2514781449 cites W2161279821 @default.
- W2514781449 cites W2165446988 @default.
- W2514781449 cites W2165455081 @default.
- W2514781449 cites W2169096816 @default.
- W2514781449 cites W2171962482 @default.
- W2514781449 cites W2226585534 @default.
- W2514781449 cites W2251610588 @default.
- W2514781449 cites W2289200040 @default.
- W2514781449 cites W2299085138 @default.
- W2514781449 cites W2299315675 @default.
- W2514781449 cites W2319565025 @default.
- W2514781449 cites W2399777411 @default.
- W2514781449 cites W2616361514 @default.
- W2514781449 cites W4250031098 @default.
- W2514781449 cites W922383587 @default.
- W2514781449 cites W941553642 @default.
- W2514781449 doi "https://doi.org/10.1038/eye.2016.174" @default.
- W2514781449 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5306454" @default.
- W2514781449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27813521" @default.
- W2514781449 hasPublicationYear "2016" @default.
- W2514781449 type Work @default.
- W2514781449 sameAs 2514781449 @default.
- W2514781449 citedByCount "15" @default.
- W2514781449 countsByYear W25147814492016 @default.
- W2514781449 countsByYear W25147814492017 @default.
- W2514781449 countsByYear W25147814492018 @default.
- W2514781449 countsByYear W25147814492019 @default.
- W2514781449 countsByYear W25147814492020 @default.
- W2514781449 countsByYear W25147814492021 @default.
- W2514781449 countsByYear W25147814492022 @default.
- W2514781449 countsByYear W25147814492023 @default.
- W2514781449 crossrefType "journal-article" @default.
- W2514781449 hasAuthorship W2514781449A5019950558 @default.
- W2514781449 hasAuthorship W2514781449A5063176118 @default.
- W2514781449 hasAuthorship W2514781449A5064089237 @default.
- W2514781449 hasAuthorship W2514781449A5067288250 @default.
- W2514781449 hasBestOaLocation W25147814491 @default.
- W2514781449 hasConcept C118487528 @default.
- W2514781449 hasConcept C126322002 @default.
- W2514781449 hasConcept C134018914 @default.
- W2514781449 hasConcept C141071460 @default.
- W2514781449 hasConcept C2776694085 @default.
- W2514781449 hasConcept C2777802072 @default.
- W2514781449 hasConcept C2778749236 @default.
- W2514781449 hasConcept C2779829184 @default.
- W2514781449 hasConcept C2780699112 @default.
- W2514781449 hasConcept C2781100027 @default.
- W2514781449 hasConcept C2781413609 @default.
- W2514781449 hasConcept C2985127711 @default.
- W2514781449 hasConcept C535046627 @default.
- W2514781449 hasConcept C555293320 @default.